Publications by authors named "Giora Mavligit"
Background: Approximately 25% of patients with metastatic breast carcinoma develop hepatic involvement during the course of their disease that further affects their survival. Systemic paclitaxel is safe and has demonstrated good antitumor activity against breast carcinoma. The objective of this prospective study was to determine the safety and antitumor activity of hepatic intra-arterial paclitaxel therapy.
View Article and Find Full Text PDFArticle Synopsis
- Patients with colorectal cancer often experience liver metastases, which can worsen their condition and limit the effectiveness of systemic therapies.
- Hepatic arterial infusion (HAI) delivers high concentrations of chemotherapy directly to liver tumors and has shown better response rates compared to intravenous chemotherapy in several randomized trials.
- However, improved survival rates were primarily noted when HAI was used alongside systemic chemotherapy after surgical removal of tumors, indicating the need for further research on combined treatment strategies, especially for patients who cannot undergo surgery.